REMUS Remus Pharma. Q2 FY26 results (Jul–Sep 2025) and concall
Remus Pharma reported strong H1 FY26 results with consolidated revenue up 47% YoY to ₹400 crores, driven by growth in both standalone and subsidiary operations. The company is strategically shifting towards higher-margin B2C segments, with its share increasing from 4% to 13%. However, consolidated margins remain lower due to the significant contribution from the high-volume, low-margin US RLD distribution business, which accounts for approximately 80% of total revenue.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
What they filed
Q2 FY26: revenue up 62.1%, net profit up 50.0% against the same quarter last year.
| Line item | Q2 FY23 | Q4 FY23 | Q2 FY24 | Q4 FY24 | Q2 FY25 | Q4 FY25 | Q2 FY26 |
|---|---|---|---|---|---|---|---|
| Revenue | 20 | 25 | 29 | 36 | 38 +90% | 41 +64% | 47 +62% |
| EBITDA | 5 | 6 | 9 | 12 | 11 +120% | 15 +150% | 15 +67% |
| Net profit | 4 | 4 | 8 | 9 | 9 +125% | 11 +175% | 12 +50% |
How to read this
₹ crore, as filed. The percentage beside a figure is the change against the same quarter a year earlier — never the quarter before, which would make every seasonal business look like it collapses and booms each year.
Inve summary of a publicly available earnings call transcript; see how call summaries are prepared. Not investment advice.
